SPARC is considered by some as a cancer therapeutic agent due to its ability to inhibit proliferation and enhance apoptosis in the ovary, colorectum, pancreas, neuroblastoma, and leukemia [19]. This evidence concerns the gene SPARC and neuroblastoma.